• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Respiratory/Inflammation

  • Efficacy and tolerability study of Symbicort Turbuhaler(160/4.5μg/inhalation,2inhalations twice daily) added to Atrovent (20μg/inhalation, 2 inhalations 4 times daily)+theophylline SR(0.1g/tablet,1 tablet p.o. twice daily) compared with Atrovent+theophylline SR in severe COPD patients

Disease
chronic obstructive pulmonary disease
Drug Name
Symbicort Turbuhaler
Generic Name
Symbicort
Sponsor
AstraZeneca
Drug Status
Approved Medicine
Phase
IV
Start Date
Jan 18, 1971
Study Name
SECURE 2
Study Id
D589BL00022
ClinicalTrials.gov ID

NCT01415518

Recruiting Status
Closed
Protocol Status
Not Available
Report Status
Not Available

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013